Status:
COMPLETED
Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Hypertension
Type 2 Diabetes
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.
Eligibility Criteria
Inclusion
- essential hypertension,
- diabetes type 2
Exclusion
- severe cardiovascular disease,
- grade 3 hypertension,
- secondary hypertension,
- abnormal liver enzymes
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT00160160
Start Date
October 1 2004
Last Update
January 30 2009
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 26
Calgary, Canada
2
Site 27
Montreal, Canada
3
Site 30
Québec, Canada
4
Site 31
Thornhill, Canada